Scholarlink

Background <p>Dyslipidaemia is a major risk factor for cardiovascular and cerebrovascular diseases; however, the optimal frequency of medical visits remains unclear.</p> Objective <p>To examine whether medical visit frequency is associated with the incidence of cardiac events, cerebrovascular events, and mortality among patients initiating lipid-lowering therapy.</p> Methods <p>We conducted a retrospective cohort study using data from the Shizuoka Kokuho Database between April 1, 2012, and September 30, 2021. Patients initiating lipid-lowering therapy were classified into high-frequency (≥ 22 visits in 2 years) and low-frequency (8–12 visits in 2 years) groups. After 1:3 propensity score matching and exclusion of patients with events within 2 years, 1,435 patients in the low-frequency group and 4,412 in the high-frequency group were analysed.</p> Results <p>Over a mean follow-up of 5.3 years, composite outcomes occurred in 5.6% of both groups (hazard ratio [HR] 1.08; 95% confidence interval [CI] 0.84–1.38; <i>p</i> = 0.571). No significant differences were observed for cardiac events (HR 1.13; 95% CI 0.83–1.54), cerebrovascular events (HR 1.13; 95% CI 0.67–1.90), or mortality (HR 0.94; 95% CI 0.60–1.48).</p> Conclusion <p>Less frequent visits were not associated with increased risks of cardiovascular events or mortality. Extending visit intervals may therefore be a reasonable option for selected stable patients receiving lipid-lowering therapy for primary prevention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association of medical visit frequency with cardiovascular events and mortality in patients with dyslipidaemia: a cohort study using a Japanese claims database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月2日

查看全文
  • Taku Matsunaga,
  • Eiji Nakatani,
  • Yasuto Sato,
  • Hideaki Kaneda,
  • Hiromitsu Ohno,
  • Akira Sugawara

摘要

Background

Dyslipidaemia is a major risk factor for cardiovascular and cerebrovascular diseases; however, the optimal frequency of medical visits remains unclear.

Objective

To examine whether medical visit frequency is associated with the incidence of cardiac events, cerebrovascular events, and mortality among patients initiating lipid-lowering therapy.

Methods

We conducted a retrospective cohort study using data from the Shizuoka Kokuho Database between April 1, 2012, and September 30, 2021. Patients initiating lipid-lowering therapy were classified into high-frequency (≥ 22 visits in 2 years) and low-frequency (8–12 visits in 2 years) groups. After 1:3 propensity score matching and exclusion of patients with events within 2 years, 1,435 patients in the low-frequency group and 4,412 in the high-frequency group were analysed.

Results

Over a mean follow-up of 5.3 years, composite outcomes occurred in 5.6% of both groups (hazard ratio [HR] 1.08; 95% confidence interval [CI] 0.84–1.38; p = 0.571). No significant differences were observed for cardiac events (HR 1.13; 95% CI 0.83–1.54), cerebrovascular events (HR 1.13; 95% CI 0.67–1.90), or mortality (HR 0.94; 95% CI 0.60–1.48).

Conclusion

Less frequent visits were not associated with increased risks of cardiovascular events or mortality. Extending visit intervals may therefore be a reasonable option for selected stable patients receiving lipid-lowering therapy for primary prevention.